Helus Pharma (HELP) Accelerates Phase 3 Pipeline Development Following CEO Dismissal and the Hiring of Robert Langer
Background of Sudden CEO Dismissal and Governance Risk
Helus Pharma (Nasdaq: HELP) board of directors abruptly demanded the resignation of Chief Executive Officer Michael Cola, who had been in the role for only two months, and approved it immediately. The outgoing CEO, Cola, is an industry veteran who previously served as head of the specialty pharmaceuticals division at Shire, acquired by Takeda, and drove the growth of blockbuster brands such as the ADHD treatment Vyvanse, making this action highly unusual. The board’s analysis suggests that strategic disagreements between the board and senior management led to the swift dismissal. The company reinstated co‑founder and Executive Chairman Eric So as interim CEO to minimize the management gap. While governance risk has expanded in the short term, the rapid transition to an interim leadership reflects the board’s strong commitment to preserving pipeline development continuity.
Strengthening Clinical Capability Through Augmentation of the Scientific Advisory Board
Amid the leadership vacuum, Helus Pharma sought to reverse the situation by recruiting high‑profile executives from the global biotech sector to its Scientific Advisory Board. Dr. Robert Langer, a world‑renowned expert in drug delivery who co‑founded Moderna and has been involved in the creation of more than 40 biotech ventures, joined the board. In addition, Dr. Stephen Brannan, former Chief Medical Officer of Karuna Therapeutics—a company recently acquired by BMS for $14 billion—was also added to the advisory panel. Their appointments are expected to offset the loss of external credibility caused by the CEO’s departure and to substantially enhance the company’s capacity for clinical trial design and regulatory engagement in the development of next‑generation neuropsychiatric therapeutics.
Outlook for Phase 3 Development of Core Pipeline Candidate HLP003
Helus Pharma’s mid‑to‑long‑term valuation is directly tied to the clinical success of its lead pipeline candidate HLP003 (formerly CYB003). HLP003 is an oral deuterated psilocin derivative targeting patients with Major Depressive Disorder and is currently being evaluated in the Phase 3 PARADIGM program. The compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and targets the serotonin 2A receptor (5‑HT2A), offering a faster onset of action and a shorter duration of psychedelic effects compared with existing therapies. Support from neuropsychiatric clinical design experts on the Scientific Advisory Board is expected to accelerate the generation of pivotal Phase 3 data slated for release in 2026 and to drive the development of a commercialization strategy.
Competitive Landscape in the Neuropsychiatric Market and Impact on Corporate Valuation
The Major Depressive Disorder treatment market was valued at approximately $6.3 billion in 2025 and is projected to grow at a compound annual growth rate of 3.9% through 2030, reaching roughly $7.5 billion. Helus Pharma is engaged in an intense race for market leadership against Phase 3 competitors such as COMP360 from Compass Pathways. While rapid clinical success is essential for competitive positioning, the recent CEO change could introduce a negative variable for strategic fundraising and global partnership negotiations. However, the addition of Dr. Brannan, who drove Karuna’s success, is expected to enhance Helus Pharma’s prospects for clinical and commercial success, serving as a key catalyst for long‑term value recovery.
The resignation of Helus Pharma’s (HELP) Chief Executive Officer raises concerns about short‑term financing and potential delays in strategic partnership negotiations within the Major Depressive Disorder (MDD) treatment market, which is projected to grow at a 3.9% CAGR to $7.5 billion by 2030. However, the inclusion of Dr. Robert Langer, co‑founder of Moderna, and Dr. Stephen Brannan, a key figure behind Karuna Therapeutics’ success, on the Scientific Advisory Board serves as a powerful mitigation of clinical risk. Their expertise is expected to accelerate the Phase 3 trial timeline and improve the success probability of HLP003, the core candidate that targets the serotonin 2A receptor and has received FDA Breakthrough Therapy Designation. Consequently, over the medium to long term, Helus Pharma is likely to secure differentiated clinical data and regulatory approval relative to strong competitors such as COMP360 from Compass Pathways, preserving the company’s fundamental valuation.